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Relapse preventionObjective:Relapse and acute exacerbation are common in schizophrenia andmay impact treatment response and
outcome. Evidence is conﬂicting in respect to superiority of long-acting injectable antipsychotic therapies versus
oral antipsychotics in relapse prevention. This randomized controlled study assessed the efﬁcacy of paliperidone
palmitate versus oral antipsychotics for relapse prevention.
Method: Eligible patients with a recent diagnosis of schizophrenia (within 1–5 years) were randomized 1:1 to
paliperidone palmitate (n = 376) or oral antipsychotic monotherapy (n = 388) and entered a 2-week initial
acute oral treatment phase. Patients who met predeﬁned response criteria were eligible to enter the 24-month
rater-blinded core treatment phase. Patients were evaluated for relapse, symptoms, functioning, quality of life,
treatment satisfaction, and tolerability.
Results: In the core treatment phase, time to relapse was signiﬁcantly longer in the paliperidone palmitate
(n= 352) comparedwith the oral antipsychotics arm (n=363): 85% of patientswere relapse-free at 469 versus
249 days (P = 0.019). Signiﬁcantly fewer patients receiving paliperidone palmitate met the relapse criteria
(52 [14.8%] versus 76 [20.9%, oral antipsychotics]; P= 0.032), representing a 29.4% relative risk reduction. For
paliperidone palmitate, a signiﬁcantly greater improvement in Positive and Negative Syndrome Scale total
score on Day 8 (P = 0.021) and a trend at endpoint (P = 0.075) were observed. Functioning improvements
were comparable between treatment arms. No new safety signals were identiﬁed.
Conclusion: The observed time to relapse superiority of paliperidone palmitate over oral antipsychotics provides
further evidence for the value of long-acting injectable antipsychotic therapies in the treatment of schizophrenia,
including during the early stages of illness.
© 2015 Janssen Pharmaceutica NV. Published by Elsevier B.V. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Despite the availability of effective treatment for schizophrenia, re-
lapse and acute exacerbations are common (Emsley et al., 2013a). Re-
sponse to treatment after relapse is variable; some patients displayy Elsevier B.V. This is an open access aemergent refractoriness following relapse even when the interval be-
tween onset of ﬁrst relapse symptoms and initiation of treatment is
brief (Emsley et al., 2013b).
Evidence regarding the superiority of long-acting injectable antipsy-
chotic therapies (LATs) over oral antipsychotics in terms of relapse pre-
vention is conﬂicting (Leucht et al., 2011; Kishimoto et al., 2013;
Kishimoto et al., 2014), with long-term comparisons scarce (Kane
et al., 2010; Rosenheck et al., 2011). Hence, naturalistic andrticle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
394 A. Schreiner et al. / Schizophrenia Research 169 (2015) 393–399appropriately designed studies are needed to compare these treatment
options (Kirson et al., 2013; Alphs et al., 2014), particularly in recently
diagnosed patients with schizophrenia. The Prevention of Relapse
with Oral Antipsychotics versus Injectable Paliperidone Palmitate
(PROSIPAL) study was a randomized controlled, open-label, rater-
blinded study that assessed the efﬁcacy of paliperidone palmitate (PP)
(Janssen-Cilag International NV, 2015), an atypical LAT, compared
with oral antipsychotic monotherapy, in recently diagnosed patients
with schizophrenia.
2. Methods
2.1. Study design
This multicenter, randomized, prospective, active-controlled, open-
label, rater-blinded, international 24-month study in recently diagnosed
(within 1–5 years) patients with schizophrenia (NCT01081769) was
conducted in 141 centers across 26 countries (Appendix); it comprised
a 2-week initial acute oral treatment phase and a 24-month core treat-
ment phase.
Patients expected by the investigator to beneﬁt from switching to
one of the study medications were eligible to enter the initial acute
oral treatment phase; patients were eligible for the core treatment
phase if they then met all predeﬁned response criteria:
• A score of ≤4 for at least four of the following Positive and Negative
Syndrome Scale (PANSS) items: P1 (delusions), P2 (conceptual disor-
ganization), P3 (hallucinatory behavior), P6 (suspiciousness/persecu-
tion), P7 (hostility), and G8 (uncooperativeness) and
• Clinical Global Impression-Severity (CGI-S) score ≤ 4, and
• No intolerable side effects of study medication.
Patients were maintained on PP or on the same oral antipsychotic
(aripiprazole, quetiapine, olanzapine, paliperidone extended-release
[ER], risperidone, or haloperidol as clinically indicated by the investiga-
tor) until the end of the core treatment phase, or until relapse or with-
drawal from study.
The protocol was reviewed and approved by the Independent Ethics
Committee/Institutional Review Board in each participating country.
The studywas conducted in accordancewith the Declaration of Helsinki
(2008) and Good Clinical Practice (International Conference on
Harmonisation). Eligible patients were informed of the risks and bene-
ﬁts of the trial and were required to provide written informed consent
for participation during an initial screening visit (Visit 1 [Day−14]).
Standard medical and psychiatric assessments were completed to con-
ﬁrm the patients' clinical history and current symptomatology.
2.2. Subjects
2.2.1. Key inclusion criteria
Patients experiencing an acute episode of schizophrenia with a
PANSS total score of 70–120 at screening were eligible for this study if
aged 18–65 years, with a diagnosis of schizophrenia according to the
Diagnostic and Statistical Manual of Mental Disorders (Fourth edition)
criteriamade 1–5 years previously and a history of ≥2 relapses requiring
psychiatric hospitalization in the preceding 24 months; this may have
included the current acute episode.
2.2.2. Key exclusion criteria
Patients were not eligible if they were antipsychotic-naive, consid-
ered by the investigator to be treatment-resistant or unsuitable for
treatment with an atypical oral antipsychotic or oral haloperidol mono-
therapy, or had received clozapine within the previous 3 months. Other
exclusion criteria included use of LATs within three injection cycles be-
fore screening, starting a psychotherapy program within 2 monthspreceding baseline, a history or current symptoms of tardive dyskinesia
or a history of neuroleptic malignant syndrome, or involuntary
hospitalization.
2.3. Treatment
2.3.1. Initial 2-week acute oral treatment phase
After screening, patients were randomized (1:1) to either PP or oral
antipsychotic treatment and immediately entered the 2-week initial
acute oral treatment phase. Patients randomized to PP had their previ-
ous oral antipsychotic replaced with oral paliperidone ER (dose range:
3–12 mg once daily). Patients randomized to oral antipsychotics had
their previous oral antipsychotic (Supplementary Table 1) replaced
with an oral antipsychotic different to the one they were using when
they relapsed, as clinically indicated by the investigator. In both treat-
ment arms, previous oral antipsychotics were tapered off over a maxi-
mum of 7 days.
A maximum of ﬁve, from a possible six, different oral antipsychotics
(haloperidol plus four out of ﬁve oral atypical antipsychotics) were avail-
able to each study site; investigators could choose to prescribe any to the
ﬁrst randomized patient at their site. Subsequent patients were each pre-
scribed a different oral antipsychotic at the investigator's discretion, to en-
sure equal distribution ofmedications. If ≥4 patientswere allocated to the
oral antipsychotic arm at a single site, all treatments were again made
available to that site such that for the ﬁfth patient the investigator was
again able to choose from ﬁve oral antipsychotics. Oral antipsychotics
were dispensed for self-administration and at each visit; patients were
reminded to take their medication. The investigator or designated study
personnel maintained a log of all drugs dispensed and returned (pill
counts) at each visit; no routine blood level tests were conducted. Drug
supplies for each patient were inventoried and accounted for throughout
the study.
2.3.2. 24-month core treatment phase
Patients randomized to PP received intramuscular PP 150 mg eq. on
Day 1 (deltoid), 100 mg eq. on Day 8 (deltoid), 75 mg eq. on Day 38
(deltoid or gluteal), and once monthly thereafter with ﬂexible dosing
25–150 mg eq. (deltoid or gluteal). Patients randomized to the oral an-
tipsychotic arm continued on the same drug that they had been pre-
scribed in the initial acute oral treatment phase, at the dose deﬁned by
the investigator. Dose adjustments were permissible throughout the
study within the locally-approved dose range. Assessments were
performed on Day 1, Day 8, and then monthly for the ﬁrst 4 months,
at 6 months and quarterly thereafter until Month 24. Adverse events
and concomitant medications were recorded continuously. Upon re-
lapse, treatment with study medication was terminated; an alternative
antipsychotic could be started at the investigator's discretion.
2.4. Efﬁcacy assessments
The primary efﬁcacy outcome was time to relapse per criteria de-
scribed by Csernansky et al. (2002) (Appendix). Secondary outcomes
included the proportion of patients with relapse at endpoint, PANSS
total and subscale scores, Marder factor scores (Marder et al., 1997),
percentage of treatment responders (≥30% decrease in PANSS total
score from baseline to last observation carried forward endpoint
[LOCF, 24months or at early discontinuation]), CGI-S and Clinical Global
Impression-Change (CGI-C) (Guy, 1972), Personal and Social Perfor-
mance (PSP) scale (Morosini et al., 2000), Short Form (36) Health Sur-
vey (SF-36) (Ware and Sherbourne, 1992, Ware and Gandek, 1994),
European Quality of Life-5 Dimensions (EQ-5D) (EuroQol Group,
1990), Subjective Well-Being under Neuroleptics Scale (SWN-S)
(Naber, 1995), patient treatment satisfaction (Treatment Satisfaction
Questionnaire for Medication; TSQM) (Atkinson et al., 2004), and
physician's treatment satisfaction (7-point categorical scale).
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Safety and tolerability assessments included treatment-emergent
adverse events (TEAEs), extrapyramidal symptoms (using the Abnor-
mal Involuntary Movement Scale [AIMS], Barnes Akathisia Rating
Scale [BARS], and Simpson Angus Rating Scale [SAS]), and changes in
body weight and body mass index. No protocol-based laboratory tests
were obligatory.
2.6. Data analysis.
The whole intent-to-treat (ITT) population included all randomized
patients who received ≥1 dose of study medication during the 2-week
initial acute oral treatment phase. The core ITT population comprised
patients who responded to the 2-week initial acute oral treatment
phase and received ≥1 dose of study medication in the 24-month core
treatment phase. Efﬁcacy and safety analyses were performed on core
ITT patients who had at least one post-baseline (Day 1 of the 24-
month core treatment phase [Visit 2, responder assessment]) efﬁcacy
or safety measurement, respectively, in the 24-month core treatment
phase.
The sample size was calculated based on the primary efﬁcacy vari-
able ‘time to a relapse event’, assuming that the proportion of patients
experiencing a relapse event during the core treatment phase would
be 20% in patients receiving PP and 30% in those receiving oral antipsy-
chotics. In total, 296patients per treatment armand143 eventswere re-
quired to detect this difference, with a power of 80% and two-tailed
signiﬁcance level of 5%. Assuming that 3% of subjects would not be in-
cluded in the survival analysis, 306 subjects per treatment group (1:1
randomization ratio) were required in the 24-month core treatment
phase.
Descriptive statistics were computed for efﬁcacy and safety assess-
ments when appropriate. All statistical analyses were two-tailed; con-
clusions were based on 5% signiﬁcance. Two-sided 95% conﬁdenceFig. 1. Flow and outcomes of the study population.
*Of the study completers, 62.5% (PP) and 55.9% (oral APs) of patients completed their Month 2intervals were computed where applicable. Time to relapse was ana-
lyzed using standard methods including Kaplan–Meier product-limit
survival curve estimates for the 85th percentile, representing the lowest
percentile for which estimates for both treatment arms were available,
log-rank tests, and proportional hazard regression models. For second-
ary efﬁcacy assessments, change from baseline at each visit and at
LOCF endpoint were analyzed using theWilcoxon signed-rank test; dif-
ferences between treatment groups were analyzed using the Wilcoxon
two-sample test. Categorical variables, e.g. response rates,were evaluat-
ed using Fisher's exact test. Unless otherwise stated, all efﬁcacy assess-
ments reported at endpoint refer to LOCF endpoint.
3. Results
3.1. Baseline demographics and patient disposition
Overall, 775 patients provided informed consent; of these, 769were
randomized and entered the 2-week initial acute oral treatment phase
(Fig. 1). No signiﬁcant differences were observed between the two
arms for any baseline demographic (Table 1).
Overall, 91.5% of patients randomized to PP received the drug as
speciﬁed per protocol; mean average dose from the fourth injection in-
clusive (i.e. during the ﬂexible dosing period onwards) was 101.7 ±
29.3 mg eq. Mean modal daily doses of the oral antipsychotics are de-
scribed in Table 2.
3.2. Efﬁcacy outcomes
Time to relapse (primary outcome) was signiﬁcantly longer in
patients receiving PP comparedwith those receiving oral antipsychotics
(P= 0.019; hazard ratio 1.5; 95% conﬁdence interval 1.1, 2.2). The 85th
percentile for time to relapse was 469 days for PP versus 249 days for
oral antipsychotics. Signiﬁcantly fewer patients receiving PP met the4 visit. AP = antipsychotic, ITT = intent-to-treat, PP = paliperidone palmitate.
Table 1
Patient demographics and baseline characteristics in the core ITT population.
Characteristic
Paliperidone palmitate
(n = 352)
Oral APs
(n = 363)
Total
(N = 715)
Mean age, years (SD) 32.6 (10.7) 32.6 (10.1) 32.6 (10.4)
Sex, n (%)
Male
Female
213 (60.5)
139 (39.5)
201 (55.4)
162 (44.6)
414 (57.9)
301 (42.1)
Mean weight, kg (SD)⁎ 74.8 (15.4) 75.7 (14.8) 75.3 (15.1)
Mean BMI, kg/m2 (SD)⁎ 25.5 (4.7) 25.8 (4.4) 25.7 (4.6)
Psychiatric history
Paranoid subtype, n (%) 308 (87.5) 308 (84.8) 616 (86.2)
Mean age at diagnosis, years (SD) 30.1 (10.6) 30.1 (10.1) 30.1 (10.4)
Mean age at start of ﬁrst AP treatment, years (SD)* 29.1 (10.5) 29.2 (10.0) 29.1 (10.2)
Mean time from diagnosis to study entry, years (SD) 3.0 (1.7) 2.9 (1.5) 2.9 (1.6)
Mean time from start of ﬁrst AP treatment to study entry, years (SD)⁎ 4.0 (3.0) 3.8 (2.4) 3.9 (2.7)
Ever been hospitalized, n (%)⁎
Previous hospitalizations, mean (SD)†
Currently hospitalized, n (%)‡
Suicide attempts since diagnosis, n (%)
1
≥2
328 (93.2)
3.1 (2.1)
106 (32.3)
12 (3.4)
10 (2.8)
332 (91.7)
3.1 (2.2)
108 (32.5)
18 (5.0)
9 (2.5)
660 (92.4)
3.1 (2.2)
214 (32.4)
30 (4.2)
19 (2.7)
Baseline PANSS total score, mean (SD)§ 82.5 (12.0) 81.5 (11.7) –
Baseline CGI-S, mean (SD)§ 3.9 (0.4) 3.8 (0.4) –
Baseline PSP total score, mean (SD)¶ 55.3 (11.3) 55.3 (11.1) –
Previous antipsychotic medications used by ≥5% patients‖, n (%)
Haloperidol 43 (12.2) 42 (11.6) 85 (11.9)
Olanzapine 36 (10.2) 21 (5.8) 57 (8.0)
Risperidone 62 (17.6) 64 (17.6) 126 (17.6)
Triﬂuoperazine 13 (3.7) 25 (6.9) 38 (5.3)
Comorbidities in N10% of patients, n (%)
Cardiovascular 37 (10.5) 38 (10.5) 75 (10.5)
Eyes, ears, nose and throat 36 (10.2) 44 (12.1) 80 (11.2)
Gastrointestinal 43 (12.2) 47 (12.9) 90 (12.6)
Neurologic 33 (9.4) 38 (10.5) 71 (9.9)
Psychiatric 35 (9.9) 44 (12.1) 79 (11.0)
AP= antipsychotic, BMI= bodymass index, CGI-S= Clinical Global Impression-Severity, ITT= intent-to-treat, n= number of patients, PANSS=Positive and Negative Syndrome Scale,
PSP = Personal and Social Performance, SD = standard deviation.
⁎ n = 352 (PP), n = 362 (oral APs).
† n = 325 (PP), n = 331 (oral APs).
‡ n = 328 (PP), n = 332 (oral APs).
§ n = 350 (PP), n = 360 (oral APs), Day 1 visit.
¶ n = 346 (PP), n = 355 (oral APs), Day 1 visit.
‖ Prior to the initial acute phase of treatment.
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0.032), representing a 29.4% relative risk reduction (Fig. 2).
Secondary outcomes are described in Supplementary Table 2. A sta-
tistically signiﬁcantly greater improvement in PANSS total scorewas ob-
served on Day 8 (mean change−4.8 versus−3.7 [oral antipsychotics];
P = 0.021); a trend in favor of PP was observed at endpoint (mean
change−16.6 versus−14.1 [oral antipsychotics]; P= 0.075) (Supple-
mentary Fig. 1). At endpoint, a ≥30% improvement in PANSS total score
was observed in 75.6% (PP) versus 69.4% (oral antipsychotics) of pa-
tients (P=0.079). Both treatment arms showed comparable signiﬁcantTable 2
Dosing (daily dose in mg) and drug exposure information for the core ITT oral APs group.
Aripiprazole
(n = 81)
Haloperidol
(n = 34)
Ola
(n =
First dose (acute phase), n 81 34 49
Mean (SD) 14.4 (5.8) 7.1 (5.2) 9.5
Range 5, 30 1, 20 5, 2
Baseline dose, n 81 34 49
Mean (SD) 17.9 (7.0) 8.3 (5.1) 12.0
Range 10, 30 2, 20 5, 2
Modal dose, n 81 34 49
Mean (SD) 19.1 (7.7) 8.2 (4.6) 12.9
Range 10, 30 2, 15 5, 2
Last dose, n 81 34 49
Mean (SD) 19.6 (7.7) 7.4 (4.3) 13.3
Range 10, 30 2, 15 5, 2
AP = antipsychotic, ER = extended release, ITT = intent-to-treat, SD = standard deviation.improvements at every time point for PANSS total score. Signiﬁcantly
greater improvements were observed in favor of PP for the PANSS
General Psychopathology subscale score at Day 8 (P = 0.018) and
endpoint (P = 0.045), and for the Marder factors ‘disorganized
thoughts’ (Day 8, P = 0.042) and ‘uncontrolled hostility/excitement’
(Day 8, P= 0.033, endpoint, P= 0.008).
At endpoint, 65.4% of patients receiving PP and 65.0% receiving oral
antipsychotics were rated mildly or less severely ill, compared with
14.0% and 16.1%, respectively, at baseline (CGI-S total score). Changes
in CGI-S from baseline to endpoint were statistically signiﬁcant withinnzapine
49)
Paliperidone ER
(n = 77)
Quetiapine
(n = 65)
Risperidone
(n = 57)
77 65 57
(4.2) 6.6 (2.4) 284.6 (174.3) 3.7 (1.6)
0 3, 12 100, 800 2, 8
76 64 57
(4.7) 7.7 (2.5) 453.1 (184.3) 4.2 (1.4)
0 3, 12 100, 800 2, 6
77 65 57
(5.2) 7.5 (2.7) 489.2 (188.0) 4.3 (1.6)
5 3, 15 100, 800 2, 8
77 65 57
(5.3) 7.8 (3.1) 501.5 (204.3) 4.3 (1.5)
5 3, 15 100, 900 2, 8
Fig. 2. Kaplan–Meier plot of time to relapse*.
*Relapse was deﬁned by any of the following: psychiatric hospitalization; an increase in the level of psychiatric care (e.g. signiﬁcant crisis intervention needed to avert hospitalization,
clinically notable increases in the frequency or intensity of patient contact required to maintain outpatient status) and an increase of 25% from BL in the Positive and Negative Syndrome
Scale total score (or an increase of 10 points if the BL score was ≤40); deliberate self-injury; suicidal or homicidal ideation that was clinically signiﬁcant in the investigator's judgment;
violent behavior resulting in clinically signiﬁcant injury to another person or property damage; substantial clinical deterioration, deﬁned as a change score of 6 (much worse) or 7
(very much worse) on the CGI-C scale; the required dose of AP exceeds the maximum approved dose. AP = antipsychotic, BL = baseline, CGI-C = Clinical Global Impression-Change,
PP = paliperidone palmitate.
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(P= 0.4837 [Supplementary Fig. 2]).
PSP total score improved signiﬁcantly from baseline to endpoint in
both groups (mean change 9.8 [PP] versus 8.7 [oral antipsychotics];
both P b 0.0001 within groups); these improvements were not signiﬁ-
cant between groups (P = 0.2831 [Supplementary Fig. 3]). Signiﬁcant
improvements in SF-36, EQ-5D, and SWN-S scores were observed in
both treatment arms (Supplementary Table 2). No signiﬁcant differ-
ences were observed between groups except for a signiﬁcantly greater
improvement in EQ-5D index score in favor of oral antipsychotics at
Month 12 (P= 0.017).
In the PP arm, TSQM signiﬁcantly improved across all domains
(P b 0.05) except the ‘side effects’ subscale score. Signiﬁcantly
greater improvements in the TSQM ‘convenience’ subscale score
were observed in favor of PP (Month 24 [P b 0.01], Month 12, and
endpoint [P b 0.0001]). There were no signiﬁcant differences in
patients' treatment satisfaction in favor of oral antipsychotics
(Supplementary Table 2) except for mean improvement from baseline
in the ‘effectiveness’ subscale score at Month 24 (P b 0.05). Greater im-
provements in physician's treatment satisfaction were observed for PP
versus oral antipsychotics in scores for ‘safety’ (Month 12, P b 0.01),
‘mode of administration’ (Months 12, 24, endpoint, P b 0.0001), and
‘overall satisfaction’ (Months 12, 24, endpoint, P b 0.05).
3.3. Safety and tolerability
The most common TEAE reported was increase in body weight
(Table 3); the proportion of patients reporting a ≥7% increase is
shown in Table 4. No new safety signals were observed in either study
arm.
In the safety ITT population (n = 715), ≥1 serious TEAEs were re-
ported in 11.6% (PP) and 12.7% (oral antipsychotics) of patients. Four-
teen (4.0%) and 11 (3.0%) patients withdrew from the study due to a
TEAE in the PP and oral antipsychotics arms, respectively. Two deaths
occurred: one of cardiac arrest (PP), considered unrelated to study
drug; and one of sudden death (oral olanzapine), considered doubtfully
related to study drug (Appendix).
The proportionof patientswith a TEAEof hyperprolactinemia and/or
at least one potentially prolactin-related TEAE was similar between
treatment arms (6.3% [PP] versus 5.0% [oral antipsychotics])(Supplementary Table 3). There were no statistically signiﬁcant differ-
ences between treatment arms in changes from baseline to endpoint
for extrapyramidal symptom rating scales (Table 3).
4. Discussion
This study aimed to provide robust evidence as to the role of LATs in
the early stages of schizophrenia. Time to relapse was signiﬁcantly lon-
ger for patients receiving PP compared with those receiving oral anti-
psychotics. The observed reduction in relative risk of relapse is
comparable with recent clinical studies and meta-analyses (Leucht
et al., 2011; Grimaldi-Bensouda et al., 2012). A recent study of injectable
aripiprazole failed to demonstrate an advantage on relapse rates over
the oral formulation (Fleischhacker et al., 2014). However, patients
were only followed for 38 weeks; an advantage may have become ap-
parent in the longer term, as observed in the present study. The relapse
rate reported herein for patients receiving PP is comparable with that
found in one of the few long-term studies of LATs in early illness,
where 8% of patients with recent-onset psychosis who showed a clinical
response to long-acting injectable risperidone (LAI-R) relapsed over
2 years (Emsley et al., 2008). Another study (Rosenheck et al., 2011)
found similar times to hospitalization between unstable patients with
schizophrenia receiving oral antipsychotics and those receiving LAI-R.
However, several factors may have contributed to this outcome, includ-
ing the smaller sample size compared with that originally planned, bi-
weekly frequency of study visits, and the chronicity and illness severity
of included patients.
In the present study, the greater observed improvement in symptom
control at Day 8, and a trend toward better symptom control at end-
point in patients receiving PP compared with oral antipsychotics, is
consistent with a 2-year, active-controlled study of patients with
schizophrenia or related disorders, in which patients randomized to
LAI-R had a signiﬁcantly greater improvement in symptomcontrol com-
paredwith those receiving oral quetiapine (Gaebel et al., 2010). Similar-
ly, a more robust reduction in psychotic symptoms was observed in
patients receiving LAI-R than in oral second generation antipsychotics
(Buckley et al., 2015). However, there was no advantage in time to re-
lapse; the authors noted that frequent clinical contact may have re-
duced relapse in both groups and the power to detect between-group
differences. Nevertheless, the absence of signiﬁcant differences
Table 3
Safety outcomes in the core ITT population for safety.
Paliperidone
palmitate
(n = 352)
Oral APs
(n = 363)
Proportion of patients reporting ≥1 TEAE, n (%) 251 (71.3) 225 (62.0)
Number of TEAEs rated as possibly, probably or
very likely related to study drug, n (%)
448 (50.3) 294 (43.8)
TEAEs occurring in ≥5% of patients, n (%)
Injection-site pain 24 (6.8) 0 (0.0)
Nasopharyngitis 25 (7.1) 18 (5.0)
Increase in weight 56 (15.9) 63 (17.4)
Headache 39 (11.1) 31 (8.5)
Tremor 18 (5.1) 8 (2.2)
Anxiety 20 (5.7) 16 (4.4)
Insomnia 34 (9.7) 29 (8.0)
Schizophrenia 29 (8.2) 35 (9.6)
Suicidal ideation 16 (4.5) 20 (5.5)
Patients reporting a potentially
prolactin-related TEAE without a TEAE of
hyperprolactinemia or blood prolactin
increased reported, n (%)
21 (6.0) 15 (4.1)
Frequency of reported
hyperprolactinemia/blood prolactin
increased without any other potentially
prolactin-related TEAE, n (%)
2 (0.6) 4 (1.1)
Potentially prolactin-related TEAEs occurring
in ≥1% of
patients, n (%)
Amenorrhea 11 (3.1) 7 (1.9)
Galactorrhea 6 (1.7) 1 (0.3)
Glucose-related TEAEs, n (%)
Diabetes mellitus inadequate control 0 (0.0) 1 (0.3)
EPS-related TEAEs occurring in ≥1% of
patients, n (%)
Akathisia 15 (4.3) 14 (3.9)
Dyskinesia 5 (1.4) 2 (0.6)
Muscle rigidity 8 (2.3) 4 (1.1)
Parkinsonism 3 (1.1) 4 (1.1)
Restlessness 4 (1.1) 1 (0.3)
Tremor 18 (5.1) 8 (2.2)
AIMS total score, Mean (SD)
Baseline 0.4 (1.3) 0.4 (1.4)
Endpoint LOCF 0.3 (0.9) 0.3 (1.4)
Change from baseline to endpoint LOCF −0.1 (1.2) −0.1 (1.4)
P value⁎ 0.1183 0.2025
P value† 0.8800
BARS total score, Mean (SD)
Baseline 0.4 (0.9) 0.4 (1.0)
Endpoint LOCF 0.3 (1.0) 0.2 (0.8)
Change from baseline to endpoint LOCF −0.1 (1.2) −0.2 (1.0)
P value⁎ 0.1772 0.0003
P value† 0.6615
SAS Global score, Mean (SD)
Baseline 0.1 (0.2) 0.2 (0.3)
Endpoint LOCF 0.1 (0.2) 0.1 (0.2)
Change from baseline to endpoint LOCF −0.1 (0.2) −0.1 (0.2)
P value⁎ b0.0001 0.0001
P value† 0.1525
Patient weight, kg, Mean (SD)
Baseline 74.8 (15.2) 76.1 (14.8)
Endpoint LOCF 77.1 (15.6) 78.0 (14.8)
Change from baseline to endpoint LOCF 2.3 (5.9) 1.9 (6.2)
P value⁎ b0.0001 b0.0001
P value† 0.2648
BMI, kg/m2, Mean (SD)
Baseline 25.5 (4.7) 25.9 (4.4)
Endpoint LOCF 26.3 (4.8) 26.6 (4.4)
Change from baseline to endpoint LOCF 0.8 (2.0) 0.7 (2.1)
P value⁎ b0.0001 b0.0001
P value† 0.2748
AIMS = Abnormal Involuntary Movement Scale, AP = antipsychotic, BARS = Barnes
Akathisia Rating Scale, BMI = body mass index, EPS = extrapyramidal symptoms, ITT =
intent-to-treat, LOCF = last observation carried forward, n = number of patients, SAS =
Simpson Angus Scale, SD= standard deviation, TEAE= treatment-emergent adverse event.
⁎ P value for within-group difference measured by Wilcoxon signed-rank test.
† P value for between-group difference measured by Wilcoxon two-sample test.
398 A. Schreiner et al. / Schizophrenia Research 169 (2015) 393–399between groups in other objective symptommeasurements, despite the
more frequent occurrence of relapse of patients in the oral treatment
arm, may reﬂect the now-recognized view that transition to relapse
can be abrupt with few/no early warning signs (Emsley et al., 2013a).
Due to the comprehensive examination of prolactin changes associ-
ated with paliperidone ER and PP in their development programs, mea-
surement of prolactin plasma levels was not required in this study. The
proportion of patients receiving PP reporting a potentially prolactin-
related TEAE in this study was similar to that reported in the develop-
ment program (107/3173; 3.4%) (Einarson et al., 2012).
Strengths of this study include the active comparator arm, 2-year
duration, randomized controlled, rater-blinded design, treatment
choice of oral AP for the investigator, high completion rates (77.3% in
the PP group and 73.3% in the oral AP group), ﬂexible dosing according
to the label, and a more naturalistic study population compared with
the pivotal studies (inclusion/exclusion criteria).
Protocol-required activities may have enhanced patient adherence
in the oral treatment arm due to the number of assessments and treat-
ment delivery controlled directly by the prescriber, including pill-count.
In particular, the discontinuation rate for patients randomized to oral
antipsychotics in this study (26.7%) was lower than that observed in
other studies of patients with early schizophrenia (Kahn et al., 2008;
McEvoy et al., 2007). Moreover, patients for whom LATs are typically
used (i.e. those who are partially or non-adherent with oral antipsy-
chotics) may be under-represented, leading to under-estimation of
the value of LATs in non-adherent patients. Nevertheless, it may be pos-
sible that some patients were not adherent to treatment e.g. discarding
medication prior to the pill count. Other limitations include the non-
blinding of medication (consequent to the required complexity of the
study design), potential bias favoring the oral arm (patients in the PP
arm had to switch treatments whereas those in the oral arm remained
on their current medication), any potential selection bias between
LATs and oral psychotics somehow inherent in the clinician's choice,
and lack of control of other non-pharmacological treatment variables
between sites. In this study, in the oral treatment arm the six most fre-
quently prescribed oral antipsychotics were offered; in order to main-
tain a balance between oral treatments, investigators were not always
able to choose among all six oral APs for individual patients. Overall,
pragmatic open-label studies are considered valuable because they
add clinically relevant information on treatment effectiveness,
complementing the evidence provided by RCTs (Kirson et al., 2013).
Despite their potential advantages, most treatment guidelines ad-
vise limiting the use of LATs to multiple-episode or non-adherent pa-
tients, with controversy in relation to their role in early schizophrenia
(Kim et al., 2012). Nevertheless, less equivocal recommendations advo-
cating their use in early illness are emerging, not least during the critical
period of the ﬁrst 2–5 years following diagnosis, when important deci-
sions in social and vocational role functioning are made (Malla et al.,
2013; Altamura et al., 2012). The superiority of PP over oral antipsychot-
ic monotherapy in time to relapse in recently diagnosed patients ob-
served in this study may help to bring greater clarity to the role of
LATs, as well as to dispel some of the reticence by psychiatrists toward
their use in the treatment of patients with schizophrenia, including
the early stages of illness. Further research in patients early in the course
of their illness is recommended.Role of the funding source
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Haloperidol
(n = 34)
Quetiapine
(n = 65)
Paliperidone ER
(n = 76)
Paliperidone palmitate
(n = 350)
Aripiprazole
(n = 81)
Risperidone
(n = 56)
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